Autolus Therapeutics Plc ADR (AUTL) said before open Thursday that it lost $0.45 per share in quarter four 2023. The company reported $0.00 in revenue
In the same quarter a year ago, the company lost $0.23 per share on revenue of $3.8 million.
The stock is up 8.39% to $5.94 after the report.
Despite Autolus Therapeutics Plc ADR reporting a decline in revenues, earnings increased signaling a rise in profit margins.
The average recommendation from Wall Street analysts was a Strong Buy which may get revised based on this new data.
Trading in the five days leading up to the report earned Autolus Therapeutics Plc ADR a Bearish Sentiment Rank from InvestorsObserver.
Prior to the report, InvestorsObserver gave the stock an overall score of 68. Meanwhile, the average Wall Street analyst rated the stock a Strong Buy.
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
News Home
Autolus Therapeutics Plc ADR Up 8.39% To $5.94 After Earnings Miss
Mentioned in this article
